Search

Your search keyword '"Mehra, Ranee"' showing total 254 results

Search Constraints

Start Over You searched for: Author "Mehra, Ranee" Remove constraint Author: "Mehra, Ranee" Database Unpaywall Remove constraint Database: Unpaywall
254 results on '"Mehra, Ranee"'

Search Results

1. Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.

2. Characterization of enhancer of zeste homolog 2 (EZH2) expression, activity, and association with the tumor immune microenvironment in olfactory neuroblastoma (ONB).

3. A phase II trial of reirradiation combined with pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (HNSCC).

8. Disease and Toxicity Outcomes for a Modern Cohort of Patients with Squamous Cell Carcinoma of Cutaneous Origin Involving the Parotid Gland: Comparison of Volumetric Modulated Arc Therapy and Pencil Beam Scanning Proton Therapy

10. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

16. Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

17. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

18. Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

19. Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

20. Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

21. Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

22. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

23. Supplementary Figure 2: T cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

24. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

25. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

26. Supplementary Figure 2: T cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

27. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

28. Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

29. Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

30. Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

31. Data from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation

32. Supplementary Figure S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

33. Supplementary Figure S3 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

34. Supplementary Figure S4 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

35. Data from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation

36. Supplemental Tables and Figure Legends from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

37. Supplementary Table S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

38. Supplementary Table S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

39. Supplementary Figure S3 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

40. Supplemental Tables and Figure Legends from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

41. Supplementary Figure Legends 1-10, Table 2 from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation

42. Supplementary Figure S2 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

43. Data from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

44. Supplementary Figure S5 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

45. Supplementary Table 1 from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation

46. Supplementary Figures 1-10 from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation

47. Data from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

48. Supplementary Figure Legends 1-10, Table 2 from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation

49. Supplementary Figures 1-10 from Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation

50. Supplementary Figure S1 from EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer

Catalog

Books, media, physical & digital resources